The objective of the City of Hope (COH) Clinical Oncology Research Career Development Program is to develop a new generation of clinical oncologic investigators capable of translating basic advances in cancer biology into novel strategies for the diagnosis, therapy, and prevention of malignant disease. This multi-disciplinary effort will be available to outstanding surgeons, radiation oncologists, pathologists, pediatricians, and internists who have completed their fellowship training in oncology, who are in the early stages of their career, and who are appropriate for appointment to the faculty of the Cancer Center. COH has pursued as one of its central goals, the enhancement of interactive basic and clinical research at the cutting edge of molecular genetics, virology and gene therapy, immunology and immunotherapy, bone marrow transplantation and stem cell biology, and experimental therapeutics. Since the inception of the COH CORCD Program in 1992, trainee enrollment has included surgical oncologists (including a urologic surgical oncologist and a neurosurgical oncologist), medical oncologists and hematologic malignancies and bone marrow transplant oncologists. Nine of the ten graduates of the Program have full-time academic positions at a NCI-designated comprehensive cancer center;the tenth is Director of Clinical Research for a pharmaceutical company. In this proposal, we describe a four-year curriculum within a 75% protected time appointment that involves both didactic and practical experience in biostatistics, clinical investigation, basic science and laboratory research for training clinical investigators at the junior faculty level. During the first year, the comprehensive core curriculum involves Methodology in Clinical Investigation, Scientific Writing, Biomedical Tools and Resources, Research Seminars, and Journal Club. Paul Calabresi Scholars will also initiate their supervised clinical research by choosing clinical and laboratory mentors. Scholars will be supervised by clinical and laboratory mentors throughout their tenure. In Year 2 and beyond, trainees will take courses in Clinical Pharmacology and three electives. Trainees will continue their experience in Research Seminars, and Journal Club, as well as the expansion of their specific supervised clinical research. The activities of the trainees will be carefully assessed during all aspects of the training period with quarterly presentations of their research progress, and meetings with Dr. Figlin, the Program Director. Requirements for satisfactory completion of the CORCD Program include the publication of a report of the trainee's clinical and/or laboratory research in a peer-reviewed journal, completion of a clinical research protocol which will be IRB approved for patient accrual, and a grant application detailing an appropriate clinical and/or laboratory study that is suitable for submission to the NIH.

Public Health Relevance

This proposal describes a program that is aimed at developing a new generation of clinical oncologic investigators capable of translating laboratory science to the clinic. It is available to those investigators in the early stages of their career. The program combines an excellent curriculum and research experience to increase the number of physician-scientists who will become leaders for advancing cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA001727-17
Application #
7935251
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (J1))
Program Officer
Lei, Ming
Project Start
1992-09-09
Project End
2014-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
17
Fiscal Year
2010
Total Cost
$740,319
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Sun, Virginia; Kim, Jae Y; Raz, Dan J et al. (2018) Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. J Cancer Educ 33:557-563
Raz, Dan J; Wu, Geena X; Consunji, Martin et al. (2018) The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography. Clin Lung Cancer 19:51-57
Sedrak, Mina S; Hurria, Arti (2018) Cancer in the older adult: Implications for therapy and future research. Cancer 124:1108-1110
Chaudhry, Ammar; Gul, Maryam; Chaudhry, Abbas (2018) Utility of computed tomography lung cancer screening and the management of computed tomography screen-detected findings. J Thorac Dis 10:1352-1355
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Callahan, Ann F; White, Michael; Ituarte, Philip et al. (2018) Surgical Intervention in Gastric Carcinoid is Associated With Improved Survival in Local and Regional Disease. Am J Clin Oncol 41:882-887
Jandial, Rahul; Neman, Josh; Lim, Punnajit P et al. (2018) Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. Int J Mol Sci 19:
Konstantinidis, Ioannis T; Nota, Carolijn; Jutric, Zeljka et al. (2018) Primary liver sarcomas in the modern era: Resection or transplantation? J Surg Oncol 117:886-891
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Chuang, Jeremy; Gong, Jun; Klempner, Samuel J et al. (2018) Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 9:560-572

Showing the most recent 10 out of 192 publications